




APAC HCC [Live Webinar](#)

PRIME: Pioneering Regional Integration of Multimodal Care and Curative Evolution

20 Oct 2026, Tuesday APAC Time zone Below



In partnership with(合辦單位):



台灣免疫暨腫瘤學會
Taiwan Society for Immunotherapy of Cancer

As the treatment landscape for unresectable hepatocellular carcinoma (uHCC) rapidly evolves, the integration of systemic therapies with locoregional interventions is opening new doors to curative outcomes. Join leading oncology experts from across the Asia-Pacific region for a dedicated cross-border scientific exchange exploring **practical clinical strategies**, **treatment sequencing**, and the **latest evidence** in uHCC disease management.

Faculty

Agenda



Moderator
Dr. Masafumi Ikeda
Medical Oncology
National Cancer Center
Hospital East
Japan

18:05-18:30

Optimising Outcomes in uHCC: Anti-VEGF
Flexibility and Locoregional Synergy
Dr. San-Chi Chen



Speaker
Dr. San-Chi Chen
Medical Oncology
Taipei Veterans
General Hospital
Taiwan

18:30-18:55

HCC Conversion Surgery in the Era of
Immunotherapy
Dr. Hong Jae Chon



Speaker
Dr. Hong Jae Chon
Medical Oncology
CHA Bundang
Medical Center
South Korea

18:55-19:25

Cross-Border Panel Discussion &
Live Q&A
Moderated by Dr. Masafumi Ikeda

Time



17:00-18:30



Indonesia



Thailand



Vietnam



18:00-19:30



Philippines



Singapore



Taiwan



Malaysia



19:00-19:30



South Korea



Scan the QR code or click [here](#) register

For Healthcare Professionals Only

Roche Singapore Pte Ltd | 1 Paya Lebar Link #09-03, PLQ 1, Paya Lebar Quarter, Singapore 408533.

This content may include scientific information about experimental or investigational compounds, indications and/ or services that are not approved or valid in your country. All information presented is for the purpose of scientific knowledge exchange only.

M-TW-00009568